<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437267</url>
  </required_header>
  <id_info>
    <org_study_id>H01_05TP</org_study_id>
    <nct_id>NCT01437267</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants</brief_title>
  <official_title>A Phase 2, Randomized, Controlled, Observer Blind, Single Center Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Children, Older Infants and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 trial is aimed to obtain information on the safety and immunogenicity of the
      Vi-CRM197 in children and infants from various age groups in the Philippines where Typhoid
      Fever is highly endemic and an efficacious vaccine against this disease is very much needed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer</measure>
    <time_frame>At 28 days after last vaccination as compared to baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titer</measure>
    <time_frame>At 6 months after last vaccination as compared to baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Vi ELISA Geometric Mean Concentration (GMC)</measure>
    <time_frame>At 28 days after last vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Vi ELISA GMC</measure>
    <time_frame>At 6 months after last vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Solicited Local and Systemic Reaction, After Any Vaccination</measure>
    <time_frame>During the 7-day follow-up period after vaccination</time_frame>
    <description>Solicited local reactions were: erythema, induration, pain/tenderness. Solicited systemic reactions were; lethargy, irritability, vomiting, diarrhoea, loss of appetite (and persistent crying in the older infants and infants age group)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Typhoid Fever</condition>
  <arm_group>
    <arm_group_label>Vi-CRM, Older infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PNC13, Older infants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi-CRM, Infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PNC13, Infants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi-CRM, Children</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi-PS, Children</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vi-CRM197 vaccine</intervention_name>
    <arm_group_label>Vi-CRM, Older infants</arm_group_label>
    <arm_group_label>Vi-CRM, Infants</arm_group_label>
    <arm_group_label>Vi-CRM, Children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal conjugate vaccine</intervention_name>
    <arm_group_label>PNC13, Older infants</arm_group_label>
    <arm_group_label>PNC13, Infants</arm_group_label>
    <arm_group_label>Vi-PS, Children</arm_group_label>
    <other_name>Prevenar 13</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vi Polysaccharide (PS) vaccine</intervention_name>
    <arm_group_label>Vi-PS, Children</arm_group_label>
    <other_name>Typherix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subjects belonging to 3 age groups will be enrolled into the trial: children (24 to 59
             months of age at enrollment), older infants (9 to 12 months of age at enrollment) and
             infants (6 weeks of age at enrolment).

          -  Written informed consent will be obtained by the parents/ guardians before enrollment
             into the trial.

          -  Infants who have been vaccinated with BCG and HBV at birth and OPV at any time since
             birth can be enrolled into the trial, while infants who have received DTwP+HBV+Hib due
             at 6 weeks of age as per local EPI schedule cannot be enrolled into the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Rosario Z Capeding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute for Tropical Medicine (RITM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine (RITM)</name>
      <address>
        <city>Alabang, Muntinlupa City</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <results_reference>
    <citation>Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, Anemona A, Habib MA, Alberto E, Juvekar S, Khan RM, Marhaba R, Ali N, Malubay N, Kawade A, Saul A, Martin LB, Podda A. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet Infect Dis. 2014 Feb;14(2):119-29. doi: 10.1016/S1473-3099(13)70241-X. Epub 2013 Nov 28.</citation>
    <PMID>24290843</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2011</study_first_submitted>
  <study_first_submitted_qc>September 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2011</study_first_posted>
  <results_first_submitted>March 5, 2014</results_first_submitted>
  <results_first_submitted_qc>March 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2014</results_first_posted>
  <last_update_submitted>March 5, 2014</last_update_submitted>
  <last_update_submitted_qc>March 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhoid Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vi-CRM, Children</title>
          <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="P2">
          <title>Vi-PS, Children</title>
          <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="P3">
          <title>Vi-CRM, Older Infants</title>
          <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="P4">
          <title>PNC13, Older Infants</title>
          <description>Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="P5">
          <title>Vi-CRM, Infants</title>
          <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="P6">
          <title>PNC13, Infants</title>
          <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was done on all enrolled subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Vi-CRM, Children</title>
          <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="B2">
          <title>Vi-PS, Children</title>
          <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="B3">
          <title>Vi-CRM, Older Infants</title>
          <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="B4">
          <title>PNC13, Older Infants</title>
          <description>Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="B5">
          <title>Vi-CRM, Infants</title>
          <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="B6">
          <title>PNC13, Infants</title>
          <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="20"/>
            <count group_id="B6" value="20"/>
            <count group_id="B7" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6 weeks to 8 weeks (infants)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months to 12 months (older infants)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months 59 months (children)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer</title>
        <time_frame>At 28 days after last vaccination as compared to baseline</time_frame>
        <population>Intention-to-treat analysis set, which included all participants who received the vaccination, those in whom at least one post-vaccination blood sample was collected, and those for whom at least one ELISA result was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Vi-CRM, Children</title>
            <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS, Children</title>
            <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O3">
            <title>Vi-CRM, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O4">
            <title>PNC13, Older Infants</title>
            <description>Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O5">
            <title>Vi-CRM, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O6">
            <title>PNC13, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer</title>
          <population>Intention-to-treat analysis set, which included all participants who received the vaccination, those in whom at least one post-vaccination blood sample was collected, and those for whom at least one ELISA result was available.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="82" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="83" upper_limit="100"/>
                    <measurement group_id="O4" value="11" lower_limit="1" upper_limit="33"/>
                    <measurement group_id="O5" value="100" lower_limit="83" upper_limit="100"/>
                    <measurement group_id="O6" value="10" lower_limit="1" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titer</title>
        <time_frame>At 6 months after last vaccination as compared to baseline</time_frame>
        <population>Intention-to-treat analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Vi-CRM, Children</title>
            <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS, Children</title>
            <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O3">
            <title>Vi-CRM, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O4">
            <title>PNC13, Older Infants</title>
            <description>Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O5">
            <title>Vi-CRM, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O6">
            <title>PNC13, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titer</title>
          <population>Intention-to-treat analysis set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="68" upper_limit="99"/>
                    <measurement group_id="O2" value="95" lower_limit="74" upper_limit="100"/>
                    <measurement group_id="O3" value="70" lower_limit="46" upper_limit="88"/>
                    <measurement group_id="O4" value="11" lower_limit="1" upper_limit="33"/>
                    <measurement group_id="O5" value="70" lower_limit="46" upper_limit="88"/>
                    <measurement group_id="O6" value="5" lower_limit="0" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-Vi ELISA Geometric Mean Concentration (GMC)</title>
        <time_frame>At 28 days after last vaccination</time_frame>
        <population>Intention-to-treat analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Vi-CRM, Children</title>
            <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS, Children</title>
            <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O3">
            <title>Vi-CRM, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O4">
            <title>PNC13, Older Infants</title>
            <description>Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O5">
            <title>Vi-CRM, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O6">
            <title>PNC13, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Vi ELISA Geometric Mean Concentration (GMC)</title>
          <population>Intention-to-treat analysis set</population>
          <units>ELISA Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255" lower_limit="174" upper_limit="375"/>
                    <measurement group_id="O2" value="107" lower_limit="72" upper_limit="159"/>
                    <measurement group_id="O3" value="129" lower_limit="83" upper_limit="200"/>
                    <measurement group_id="O4" value="3.79" lower_limit="2.41" upper_limit="5.97"/>
                    <measurement group_id="O5" value="103" lower_limit="67" upper_limit="159"/>
                    <measurement group_id="O6" value="5.05" lower_limit="3.27" upper_limit="7.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-Vi ELISA GMC</title>
        <time_frame>At 6 months after last vaccination</time_frame>
        <population>Intention-to-treat analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Vi-CRM, Children</title>
            <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS, Children</title>
            <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O3">
            <title>Vi-CRM, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O4">
            <title>PNC13, Older Infants</title>
            <description>Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O5">
            <title>Vi-CRM, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O6">
            <title>PNC13, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Vi ELISA GMC</title>
          <population>Intention-to-treat analysis set</population>
          <units>ELISA Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="34" upper_limit="76"/>
                    <measurement group_id="O2" value="45" lower_limit="30" upper_limit="68"/>
                    <measurement group_id="O3" value="21" lower_limit="14" upper_limit="31"/>
                    <measurement group_id="O4" value="3.69" lower_limit="2.41" upper_limit="5.65"/>
                    <measurement group_id="O5" value="21" lower_limit="16" upper_limit="28"/>
                    <measurement group_id="O6" value="2.64" lower_limit="1.98" upper_limit="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Solicited Local and Systemic Reaction, After Any Vaccination</title>
        <description>Solicited local reactions were: erythema, induration, pain/tenderness. Solicited systemic reactions were; lethargy, irritability, vomiting, diarrhoea, loss of appetite (and persistent crying in the older infants and infants age group)</description>
        <time_frame>During the 7-day follow-up period after vaccination</time_frame>
        <population>Analysis was done on as treated safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Vi-CRM, Children</title>
            <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Vi-PS, Children</title>
            <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O3">
            <title>Vi-CRM, Older Infants</title>
            <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O4">
            <title>PNC13, Older Infants</title>
            <description>Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
          </group>
          <group group_id="O5">
            <title>Vi-CRM, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
          </group>
          <group group_id="O6">
            <title>PNC13, Infants</title>
            <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Solicited Local and Systemic Reaction, After Any Vaccination</title>
          <description>Solicited local reactions were: erythema, induration, pain/tenderness. Solicited systemic reactions were; lethargy, irritability, vomiting, diarrhoea, loss of appetite (and persistent crying in the older infants and infants age group)</description>
          <population>Analysis was done on as treated safety population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited Adverse Events (AEs) were collected during 7-day follow period after each vaccination. Serious AEs were collected throughout the study period. Unsolicited AEs were collected collected during 28-day follow period after each vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vi-CRM, Children</title>
          <description>Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="E2">
          <title>Vi-PS, Children</title>
          <description>Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="E3">
          <title>Vi-CRM, Older Infants</title>
          <description>Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="E4">
          <title>PNC13, Older Infants</title>
          <description>Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="E5">
          <title>Vi-CRM, Infants</title>
          <description>Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine</description>
        </group>
        <group group_id="E6">
          <title>PNC13, Infants</title>
          <description>Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <description>systemic assessment for older infants and infants</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mumps</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Respiratory tract infections</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the event that no publication of the Study results has been made by NVGH within twelve (12) months of Study database lock and no proposed publication is under discussion by the publication committee, Principal Investigator may publish its own Study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Audino Podda</name_or_title>
      <organization>Novartis Vaccines Institute for Global Health</organization>
      <phone>+39 0577 243496</phone>
      <email>audino.podda@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

